NVONYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NONOF
NOVO NORDISK A S
Financials through fiscal 2025, year ended Dec 31, 2025
$38.42−0.41 (-1.06%)
Close on Oct 19, 2026
NOVO NORDISK A S revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Obesity and Diabetes care | 289.46B DKK | 271.76B DKK | 215.10B DKK | – | – | – | – | – | – | – | 93.7% | +6.5% |
| Rare disease total | 19.61B DKK | 18.64B DKK | 17.16B DKK | 20.54B DKK | 19.20B DKK | – | – | – | – | – | 6.3% | +5.2% |
| Biopharmaceuticals | – | – | – | – | – | – | – | 17.93B DKK | 18.82B DKK | 22.83B DKK | – | – |
| Diabetes and Obesity care | – | 271.76B DKK | 215.10B DKK | 156.41B DKK | 121.60B DKK | 108.02B DKK | 102.84B DKK | 93.90B DKK | 92.88B DKK | 88.95B DKK | – | – |
| Rare disease | – | – | – | 20.54B DKK | 19.20B DKK | 18.93B DKK | 19.18B DKK | 17.93B DKK | 18.82B DKK | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Obesity and Diabetes care | 126.45B DKK | 127.72B DKK | 99.62B DKK | – | – | – | – | – | – | – | -1.0% |
| Rare disease total | 1.21B DKK | 620.00M DKK | 2.95B DKK | 7.41B DKK | 9.11B DKK | – | – | – | – | – | +95.5% |
| Biopharmaceuticals | – | – | – | – | – | – | – | 9.41B DKK | 10.61B DKK | 12.33B DKK | – |
| Diabetes and Obesity care | – | 127.72B DKK | 99.62B DKK | 67.40B DKK | 49.54B DKK | 43.74B DKK | 42.64B DKK | 37.84B DKK | 38.35B DKK | 36.10B DKK | – |
| Rare disease | – | – | – | 7.41B DKK | 9.11B DKK | 10.38B DKK | 9.85B DKK | 9.41B DKK | 10.61B DKK | – | – |
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 173.17B DKK | 167.40B DKK | 127.53B DKK | 84.66B DKK | 63.01B DKK | 57.82B DKK | 57.49B DKK | 54.49B DKK | 55.83B DKK | 57.19B DKK | 56.0% | +3.4% |
| International Operations | 135.90B DKK | 123.00B DKK | 104.73B DKK | 85.85B DKK | 73.54B DKK | 65.83B DKK | 61.56B DKK | 54.92B DKK | 53.69B DKK | 52.54B DKK | 44.0% | +10.5% |
| EUCAN | 66.09B DKK | 57.55B DKK | 48.15B DKK | – | – | – | – | – | – | – | 21.4% | +14.8% |
| Emerging Markets | 30.44B DKK | 29.52B DKK | 24.78B DKK | – | – | – | – | – | – | – | 9.8% | +3.1% |
| APAC | 20.71B DKK | 17.44B DKK | 15.11B DKK | – | – | – | – | – | – | – | 6.7% | +18.8% |
| China | 18.66B DKK | 18.50B DKK | 16.69B DKK | 16.21B DKK | 16.02B DKK | 14.08B DKK | 12.84B DKK | 11.29B DKK | 10.71B DKK | 10.46B DKK | 6.0% | +0.8% |
| Region Japan & Korea | – | – | – | – | – | – | 6.45B DKK | 5.80B DKK | 6.07B DKK | 6.23B DKK | – | – |
| Non-US | – | – | – | – | – | – | – | – | 53.69B DKK | 52.54B DKK | – | – |
| North America Operations | – | – | – | – | – | – | 60.46B DKK | 56.91B DKK | 58.01B DKK | 59.24B DKK | – | – |
| Region Latin America | – | – | – | – | – | – | 4.92B DKK | 4.01B DKK | 3.70B DKK | 3.59B DKK | – | – |
| Region AAMEO | – | – | – | – | – | – | 14.09B DKK | 12.15B DKK | 12.02B DKK | 11.58B DKK | – | – |
| Region Europe | – | – | – | – | – | – | 23.26B DKK | 21.68B DKK | 21.19B DKK | 20.68B DKK | – | – |
| Rest of World | – | 33.33B DKK | 28.08B DKK | 25.40B DKK | 19.81B DKK | 17.45B DKK | 16.51B DKK | 14.41B DKK | – | – | – | – |
| EMEA | – | – | 50.87B DKK | 44.24B DKK | 37.71B DKK | 34.30B DKK | 32.21B DKK | 29.23B DKK | – | – | – | – |
| North America Operations | – | 178.17B DKK | 136.63B DKK | 91.11B DKK | 67.26B DKK | 61.12B DKK | 60.46B DKK | 56.91B DKK | – | – | – | – |
| EMEA | – | 60.40B DKK | 50.87B DKK | 44.24B DKK | – | – | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Novo Nordisk A S's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.